NCT05163522View on ClinicalTrials.gov

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

73

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

June 21, 2023

Study Completion Date

June 21, 2023

Conditions

HIV Infections

Interventions

DRUG

VH4004280

VH4004280 will be administered.

DRUG

Placebo

Placebo will be administered.

DRUG

Midazolam

Midazolam will be administered

Trial Locations (1)

89113

GSK Investigational Site, Las Vegas

Sponsors

Lead Sponsor

ViiV Healthcare

All Listed Sponsors

lead

ViiV Healthcare

INDUSTRY